Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical

Aptose Biosciences Closes $6.1M Hanmi Takeover, Delisting TSX as Clinical-Stage AML Biotech Exits Public Markets

By The Northwire Desk — AI Analysis Jun 30, 2026 · 19:32 APS · 2.14 APTOSE BIOSCIENCES INC.
Executive Summary
  • Aptose Biosciences announced the completion of its plan of arrangement with Hanmi Pharmaceutical Co. Ltd.
  • HS North America Ltd., a Hanmi subsidiary, acquired all outstanding common shares not already owned by Hanmi for C$2.41 in cash per share.
  • The transaction represents a 28% premium over the company's 30-day VWAP of C$1.88.
  • Final court approval and necessary Korean regulatory approvals were secured.
  • Shares are expected to be delisted from the Toronto Stock Exchange (TSX) around July 3, 2026.
  • The company has applied to cease reporting status under Canadian securities laws and intends to terminate public reporting requirements in the United States and Canada.
  • The arrangement was originally announced in November 2025, amended in February 2026, and closed after regulatory delays.
Material Impact
  • The closing of the acquisition provides a definitive, premium cash exit for minority shareholders, eliminating all public market and going-concern risks associated with the company.
  • The stock price is expected to converge tightly to the C$2.41 offer price (approximately $1.80 USD at prevailing FX rates, though trading has remained elevated near $2.14-$2.40 due to arbitrage and settlement mechanics).
  • Operational and clinical development of tuspetinib will continue under Hanmi's private ownership, removing the need for public capital raises or dilutive financing.
  • The market has already priced in the deal terms and premium over the past several months, limiting any additional upside or downside volatility from this specific announcement.
APS · Price
Company Overview
  • Aptose Biosciences is a clinical-stage biotechnology company focused on precision oncology therapies.
  • Its lead asset, tuspetinib, is an oral kinase inhibitor targeting SYK, FLT3, KIT, JAK1/2, and RSK2 kinases.
  • The company was developing a triplet therapy (tuspetinib + venetoclax + azacitidine) for newly diagnosed AML patients ineligible for induction chemotherapy.
  • Clinical data from the Phase 1/2 TUSCANY trial demonstrated high response rates (86.2% composite complete response) and robust minimal residual disease (MRD) negativity (86.4% in responders), including in difficult-to-treat genetic subgroups like TP53-mutated and FLT3-unmutated cases.
  • The company had no commercial revenue and relied entirely on clinical trial funding and advances from Hanmi Pharmaceutical.
Read the original news release →

More from APTOSE BIOSCIENCES INC.

Jun 15, 2026 · 07:30

Clinical data validates tuspetinib's AML potential, but acquisition hinges on delayed Korean regulatory approval.

Other May 29, 2026 · 07:30

Aptose Deal Closing Delayed to June; Hanmi Funding Secures Runway Amidst Regulatory Hurdles

Financings May 13, 2026 · 17:00

Hanmi Acquisition Delayed to May 2026 as Aptose Burns Cash Faster Than Expected

Earnings Apr 30, 2026 · 07:30

Hanmi Acquisition Closing Delayed to May as Korean Regulatory Review Continues

M&A / Property Mar 31, 2026 · 17:22

Aptose Shareholders Approve C$2.41 Hanmi Buyout as Clinical Data Validates Triplet Strategy

Earnings Mar 23, 2026 · 17:17

Aptose Bio gets Glass, Lewis support for takeover

M&A / Property